Abstract: Provided is a bone-transplant or bone-filling composition, which comprises a dihydroxybenzoic acid derivative which has been newly demonstrated to increase the activity of osteoblasts and so induce bone formation.
Abstract: The present invention describes an oil-in-water emulsion composition for wet-wipes delivering an improved body cleansing performance while providing a gentle and smooth feeling to the user.
Type:
Grant
Filed:
July 1, 2004
Date of Patent:
February 19, 2013
Assignee:
The Procter & Gamble Company
Inventors:
George Endel Deckner, Lee Ellen Drechsler, Mathias Kurt Herrlein, Ursula Christina Glaser, Randall Glenn Marsh, Antonio Martinez-Campoy, Philip Andrew Sawin
Abstract: The invention relates to the use of di-aspirin (bis(2-carboxyphenyl)succinate) and its derivatives in the treatment of colon and colorectal cancer. It also relates to novel derivatives of di-aspirin and to a method of synthesis of the di-aspirin and its derivatives.
Type:
Application
Filed:
February 15, 2011
Publication date:
February 7, 2013
Inventors:
Christopher John Perry, Iain Douglas Nicholl
Abstract: Provided is a composition comprising 5-FU and salicylic acid. This composition is useful as a treatment for warts. As opposed to conventional compositions and methods, this composition need only be applied once a day. Also provided are methods for the preparation and use of the composition for treatment of warts.
Abstract: The invention provides novel compounds and formulations of turmeric oil, fish oil, aspirin and anti-cancer drugs (paclitaxel) having anti-inflammatory, analgesic and/or anti-cancer activity.
Abstract: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include greater than 30% by weight of the active agent, and may be formulated as solutions, solids, semisolids, microparticles, or crystals. Methods related to the implantation and use of the biodegradable drug delivery systems for treating nail unit conditions are also described.
Abstract: The present disclosure provides improved compositions comprising rifabutin, clarithromycin, and clofazimine for use in the treatment of Inflammatory Bowel Diseases. In one instance, the compositions may comprise a formulation of rifabutin, clarithromycin, and clofazimine in a single dosage form, such as a capsule, tablet, etc., with one or more specific excipients.
Abstract: The invention provides compositions and methods that employ compounds that can stimulate proliferation of fibroblasts or keratinocytes and/or stimulate production of collagen by fibroblasts. These compositions and methods are useful for treating gum- and skin-related conditions.
Abstract: The present application describes a composition comprising a neuroprotective effective amount of an antioxidant acetylsalicylic acid maltol ester (AME).
Type:
Application
Filed:
August 30, 2012
Publication date:
December 27, 2012
Applicants:
Hutecs Korea Pharmaceutical Co., Ltd., Kangwon National University
Abstract: Provided in various embodiments are surface-modified hydrogels and hydrogel microparticles, methods for their preparation, and uses thereof for delivery of personal care and healthcare active ingredients, and agricultural active ingredients. In some embodiments, such hydrogels and hydrogel microparticles comprise surface coatings that are resistant to solvent washing and can act as barriers for the migration of water and/or water-compatible alcohols and actives soluble therein.
Abstract: Compositions and method of using the same for the removal of ticks embedded in the skin or tissue of a human or animal host and for preventing ticks from attaching themselves to and biting humans or other animals.
Type:
Grant
Filed:
July 7, 2011
Date of Patent:
December 4, 2012
Assignee:
Karykion Corporation
Inventors:
Carl P. Schaffner, William K. Griesinger
Abstract: A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about 10,000 to about 50,000 Daltons, the weight average molecular weight ratio of said first molecular weight distribution to said second molecular weight distribution is at least about two to one; wherein a substantially homogeneous blend of said first and second amounts of said bioabsorbable polymer is formed in a ratio of between about 50/50 to about 95/5 weight/weight percent. Also disclosed are a medical device, a method of making a medical device and a method of melt blowing a semi-crystalline polymer blend.
Type:
Application
Filed:
August 6, 2012
Publication date:
November 29, 2012
Applicant:
ETHICON, INC.
Inventors:
Sasa ANDJELIC, Benjamin D. FITZ, Jianguo Jack ZHOU
Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
Type:
Application
Filed:
February 3, 2012
Publication date:
October 25, 2012
Inventors:
Robin Mark Bannister, John Brew, Wilson Caparros-Wanderley, Gregory Alan Stoloff, Suzanne Jane Dilly, Gemma Szucs, Olga Pleguezuelos Mateo
Abstract: A reversely thermo-reversible hydrogel composition comprising a water soluble block copolymer comprising at least two blocks of polyethylene oxide and at least one block of polypropylene oxide, and at least one associative gelling adjuvant having water solubility less than 0.5 g/100 ml, preferably less than 0.3 g/100 ml at 20° C., and being capable of forming water soluble inter-molecular complexes with the water soluble block copolymer in water. The hydrogel composition exhibits improved gelling efficiency, enhanced solubility and/or stability for water sparely soluble and insoluble pharmaceutical agents. The hydrogel compositions are useful in a variety of pharmaceutical and cosmetic products and applications, such as esophageal, otic, vaginal, rectal, ophthalmic, treatments of disorders and imperfections of the skin, and treating and/or preventing alopecia and restoring and/or promoting hair growth.
Abstract: A composition comprising a glyceryl salicylate compound and/or a glycol salicylate compound. The compositions can be used to reduce the amount of moisture evaporated from skin, protect the skin from UV light, and treat aged or damaged skin.
Abstract: A pressure sensitive adhesive for medicinal application purposes, based on ethylene-vinyl acetate copolymers is characterized in that it contains as polymer component (A) an ethylene-vinyl acetate copolymer or a combination of at least two ethylene-vinyl acetate copolymers, and as component (B) an adhesive resin or a combination of adhesive resins at a portion of up to 55%-wt, relative to the sum of components (A) and (B) without active substances or other auxiliary substances.
Abstract: Provided is a composition comprising 5-FU and salicylic acid. This composition is useful as a treatment for warts. As opposed to conventional compositions and methods, this composition need only be applied once a day. Also provided are methods for the preparation and use of the composition for treatment of warts.
Abstract: A cosmetic or pharmaceutical rinse-off formulation contains 0.2% by weight to 20% by weight of a phase A; 0.1% by weight to 50% by weight of an active substance; a detergent; and the remainder being water. The phase A is a mixture of 20% by weight to 90% by weight of a surfactant mixture of isethionates, acyl lactylates and one of alkyl glutamates and alkyl glucosides and 10% by weight to 80% by weight of water, alcohol, polyol or mixtures thereof. The phase A forms multilamellar vesicles. The cosmetic or pharmaceutical rinse-off formulation is a clear product with the multilamellar vesicles of phase A having an average diameter of less than 100 nm.
Abstract: The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 400 to about 600 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 870 to about 1715 mg.
Type:
Grant
Filed:
June 1, 2009
Date of Patent:
July 10, 2012
Assignee:
Aptalis Pharma Canada Inc.
Inventors:
Carl Gauthier, Yves Dumoulin, David Powell
Abstract: Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ active agents that modulate dynein expression in the skin. Also provided are methods for screening for substances which modulate dynein expression levels and the methods of using active agents identified by the screening protocol in the treatment of skin.
Type:
Application
Filed:
November 29, 2011
Publication date:
July 5, 2012
Applicant:
AVON PRODUCTS, INC.
Inventors:
Qian ZHENG, John W. LYGA, Russell J. WYBORSKI
Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
Type:
Grant
Filed:
December 24, 2009
Date of Patent:
July 3, 2012
Assignee:
The Regents of the University of Oklahoma
Abstract: The present invention provides methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death in a patient. The invention includes use of 5-benzylamino salicylic acid (BAS) and its derivatives. Thus, the present invention provides methods for reducing neuronal death in nervous system injuries resulting from amyotrophic lateral sclerosis.
Type:
Grant
Filed:
May 24, 2010
Date of Patent:
July 3, 2012
Assignee:
Neurotech Pharmaceuticals Co., Ltd.
Inventors:
Byoung Joo Gwag, Young Ae Lee, Bo Rum Ryu, Sung Hwa Yoon, Ho Sang Moon
Abstract: The present invention provides compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death. The invention includes synthesis of 5-benzylamino salicylic acid (BAS) and its derivatives. BAS and its derivatives protect cortical neurons from toxic insults by N-methyl-D-aspartate, Zn2+, and reactive oxygen species. Thus, the present invention provides compositions and methods for treating stroke, traumatic brain and spinal cord injury, epilepsy, and neurodegenerative diseases that are accompanied by severe neuronal loss via excitotoxicity, Zn2+ neurotoxicity, and free radical neurotoxicity.
Type:
Grant
Filed:
May 24, 2010
Date of Patent:
July 3, 2012
Assignee:
Neurotech Pharmaceuticals Co., Ltd.
Inventors:
Byoung Joo Gwag, Young Ae Lee, Bo Rum Ryu, Sung Hwa Yoon, Ho Sang Moon
Abstract: The present invention relates to methods and compositions which employ low concentrations of combinations of zinc salts and antimicrobial agents in coatings for medical articles. The coatings have an anti-irritant effect and inhibit transmission of infectious disease.
Type:
Grant
Filed:
March 1, 2010
Date of Patent:
June 26, 2012
Assignee:
The Trustees of Columbia University in the City of New York
Abstract: A cosmetic composition is provided including a water-insoluble UV-A sunscreen agent having a ?max at 330-380 nm, a water-insoluble UV-B sunscreen agent having a ?max between 280 and 320 nm, and a water-soluble sunscreen agent having a ?max between 280 and 400 nm, in combination with a photo protective enhancing agent which is a stearyl alkanolamide of structure R1C(O)NR2—R3OH wherein R1 is a C17 radical, R2 is hydrogen or a C1-C6 radical, and R3 is a C2-C8 radical, in a cosmetically acceptable carrier.
Abstract: A novel skin barrier function recovery acceleration method and accelerator are provided. The present invention provides a skin barrier function recovery accelerator that comprises a TRPA1 agonist capable of activating TRPA1 in epidermal cells.
Abstract: Single use, substrate uniformly impregnated with an anhydrous muscle and joint pain relief solution for the use of aseptically delivering a single dose of a muscle and joint pain relief solution to the area of pain. Solution and substrate is contained encapsulated within a heat sealed foil enclosure that is stable for at least five years.
Abstract: A medicinal composition includes an active medicinal substance in therapeutic dose and a potentiated medicinal preparation produced from the substance by homeopathis methods.
Abstract: The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound.
Abstract: Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described.
Abstract: Provided herein are essential oils and synthetic compounds, and combinations thereof, as repellent compositions for repelling insects, such as vespid social wasps (Vespidae), including yellowjackets, paper wasps, and hornets. Controlled release devices comprising these repellent compositions are also provided.
Type:
Application
Filed:
August 9, 2011
Publication date:
May 3, 2012
Applicant:
Sterling International Inc.
Inventors:
Rodney G. Schneidmiller, Qing-He Zhang, Doreen R. Hoover
Abstract: Water-soluble or water-swellable polymers are described, containing a) 20.0 to 98.99 mole percent of one or more independently recurring structural units of the formula (1) and b) 1.0 to 79.99 mole percent of one or more independently recurring structural units of the formula (2), and c) 0.01 to 8.0 mole percent of one or more independently recurring cross-linking structural units, which are obtained from one or more monomers having at least two olefinic double bonds. The polymers are suitable, for example, as thickeners or yield point formers, in particular in cosmetic, dermatological or pharmaceutical compositions.
Type:
Application
Filed:
March 20, 2010
Publication date:
April 26, 2012
Applicant:
CLARIANT FINANCE (BVI) LIMITED
Inventors:
Klug Peter, Dirk Fischer, Thomas Lindner, Matthias Kunze, Wiebke Moeller, Carina Mildner, Sebastiano Lo Vasco
Abstract: Topical compositions are provided that have 0.5% or more of at least one personal care or pharmaceutical acid, and lightly- to moderately-crosslinked PVP, which is an effective thickener in the low pH systems. In preferred embodiments, the acid is a hydroxy acid and the composition used for personal care, or prescriptive or non-prescriptive medication indications for use on the skin, hair, scalp, foot, or lips. Also provided is the use of the topical compositions to deliver the acid(s) to the skin, hair, scalp, foot, or lips. Especially preferred is a use to reduce irritation and stinging compared to an equivalent compositions not having lightly- to moderately-crosslinked PVP.
Type:
Application
Filed:
March 11, 2010
Publication date:
April 19, 2012
Applicant:
ISP INVESTMENTS INC.
Inventors:
Hani Fares, Chris Barrett, Tracey Ross, Anthony Luschen
Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.
Type:
Application
Filed:
December 15, 2011
Publication date:
April 12, 2012
Applicant:
AmDerma Pharmaceuticals, LLC
Inventors:
Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
Abstract: Methods for killing insects and a nest are disclosed. The methods may be used to disrupt a colony of nestdwelling insects. The insects may include wasps, hornets, and yellowjackets.
Type:
Application
Filed:
September 30, 2011
Publication date:
April 12, 2012
Applicant:
STERLING INTERNATIONAL INC.
Inventors:
Rodney G. Schneidmiller, Qing-He Zhang, Guiji Zhou, Doreen R. Hoover
Abstract: A skin engaging member suitable for use in a hair removal device, said skin engaging member comprising an encapsulated active contained in a matrix material, an encapsulated active comprising at least one nano-particle encapsulated in a micro-particle, wherein said nano-particle comprises a shell comprising a hydrophobic material, and wherein said micro-particle comprises a shell comprising a water sensitive material; and wherein at least one of said nano-particle and said micro-particle comprises a skin care active.
Abstract: By incorporating certain pharmaceutical and cosmetic preservative agents into nail polish vehicles containing corrosive ingredients, the risk and prevalence of recurrence of verrucae can be substantially reduced.
Abstract: Provided herein are compositions and methods for the treatment of soft tissue injury, sports-related injury, physical overuse of muscles, ligaments or joints, and trauma, traumatic stress or sudden jolts on bones and tissues in an individual. Described herein are pharmaceutical compositions comprising a vasoconstrictor and, optionally, a topical analgesic and methods of using said compositions for the treatment of a variety of soft tissue injuries.
Abstract: Disposable absorbent articles comprising an absorbent material and an antimicrobial composition are disclosed. The antimicrobial composition includes a carrier comprising fatty alcohol and a poly(alkyleneoxy) polymer, and an antimicrobial agent. The antimicrobial composition may be coated on to component substrates such as nonwovens and films, that are incorporated into disposable absorbent articles, such as disposable infant diapers, adult incontinence articles, feminine hygiene articles such as sanitary napkins, wound dressings, bandages, panty liners and tampons, personal care wipes and household wipes to provide odor control, and control of microbial growth.
Type:
Application
Filed:
September 17, 2010
Publication date:
March 22, 2012
Inventors:
David T. Amos, Bathsheba E. Chong Conklin, Alexis S. Statham, Michael J. Svarovsky, Leigh E. Wood
Abstract: The present invention relates to methods for treating, preventing, minimizing, and/or diminishing signs of aging in the skin comprising administering to the subject in need thereof a nanoemulsion composition.
Abstract: The present invention provides the use of surface active proteins, especially class I and class II hydrophobins, in topically applied pharmaceutical formulations. The invention is particularly directed to topically applied pharmaceutical products for enhancing the penetration to achieve a transungual delivery of a prophylactically and/or therapeutically effective amount of an active ingredient (drug) to a patient (including animals and humans) into and/or through a nail, of the animal or human body, in order to treat one or more of a variety of diseases or disorders. Related embodiments of the invention are also disclosed.
Type:
Application
Filed:
February 19, 2010
Publication date:
March 8, 2012
Applicant:
BASF SE
Inventors:
Andreas Buthe, Andreas Hafner, Franz Kaufmann, Babette Fiedler, Guido Meurer, Gordon Bradley
Abstract: Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound.
Abstract: A novel antiseptic agent composition which has a wide antimicrobial spectrum and excellent antiseptic properties is provided. An antiseptic agent composition A contains a glycerin hydroxy fatty acid monoester that is an ester of glycerin and a hydroxy fatty acid having 8 to 18 carbon atoms, and a specific antiseptic agent such as an alkanediol. An antiseptic agent composition B contains the glycerin hydroxy fatty acid monoester and an aromatic antiseptic agent. An antiseptic agent composition C contains the glycerin hydroxy fatty acid monoester and a chelating agent.
Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
Type:
Grant
Filed:
March 11, 2009
Date of Patent:
February 21, 2012
Assignee:
The Board of Regents of the University of Oklahoma
Abstract: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA).
Type:
Application
Filed:
October 26, 2009
Publication date:
February 16, 2012
Applicant:
LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
Abstract: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer.
Type:
Grant
Filed:
December 29, 2010
Date of Patent:
February 14, 2012
Assignee:
Antibe Therapeutics Inc.
Inventors:
John L. Wallace, Giuseppe Cirino, Giuseppe Caliendo, Anna Sparatore, Vicenzo Santagada, Stefano Fiorucci
Abstract: The present invention includes salts and polymorphs of flupirtine including, but not limited to carboxylic acid salts and sulfonic acid salts and their polymorphs. The present invention also includes pharmaceutical compositions comprising the salts and polymorphs of flupirtine. The invention also relates to the therapeutic use of the flupirtine salts and polymorphs to treat nervous system disorders, pain disorders, musculoskeletal disorders, and other diseases and conditions.